RNA-Seq Accurately Identifies Cancer Biomarker Signatures to Distinguish Tissue of Origin

Neoplasia (United States)

Volumn 16, Issue 11, 2014, Pages 918-927

  Wei, Iris H ^a   Shi, Yang ^a   Jiang, Hui ^a   Kumar Sinha, Chandan ^a   Chinnaiyan, Arul M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME; TUMOR MARKER;

ALGORITHM; AREA UNDER THE CURVE; ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CANCER TISSUE; COLORECTAL CANCER; GENOME; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; METASTASIS; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; RNA SEQUENCE; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; BIOLOGICAL MODEL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MALE; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SEQUENCE ANALYSIS; STATISTICAL MODEL; TUMOR CELL LINE;

ALGORITHMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOGISTIC MODELS; MALE; MODELS, GENETIC; NEOPLASMS, UNKNOWN PRIMARY; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, RNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84937541141     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.09.007     Document Type: Article

References (100)

1. Pimiento J.M., Teso D., Malkan A., Dudrick S.J., Palesty J.A. Cancer of unknown primary origin: a decade of experience in a community-based hospital. Am J Surg 2007, 194:833-837. [discussion 837-838].
2. Pavlidis N., Pentheroudakis G. Cancer of unknown primary site: 20 questions to be answered. Ann Oncol 2010, 21(Suppl. 7):vii303-vii307.
3. Shaw P.H., Adams R., Jordan C., Crosby T.D. A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network. Clin Oncol (R Coll Radiol) 2007, 19:87-95.
4. Pavlidis N., Briasoulis E., Hainsworth J., Greco F.A. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003, 39:1990-2005.
5. Hainsworth J.D., Greco F.A. Treatment of patients with cancer of an unknown primary site. N Engl J Med 1993, 329:257-263.
6. Blaszyk H., Hartmann A., Bjornsson J. Cancer of unknown primary: clinicopathologic correlations. APMIS 2003, 111:1089-1094.
7. National Comprehensive Cancer Network clinical Practice Gidelines in Oncology. Occult Primary (Cancer of Unknown Primary [CUP]). Version 3 2014, [nccn.org].
8. Werling R.W., Yaziji H., Bacchi C.E., Gown A.M. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: An immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003, 27:303-310.
9. Kaufmann O., Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 2000, 36:8-16.
10. Dennis J.L., Hvidsten T.R., Wit E.C., Komorowski J., Bell A.K., Downie I., Mooney J., Verbeke C., Bellamy C., Keith W.N., et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005, 11:3766-3772.
11. Kaufmann O., Fietze E., Mengs J., Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001, 116:823-830.
12. Motzer R.J., Rodriguez E., Reuter V.E., Bosl G.J., Mazumdar M., Chaganti R.S. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J Clin Oncol 1995, 13:274-282.
13. Atkin N.B., Baker M.C. Specific chromosome change, i(12p), in testicular tumours?. Lancet 1982, 2:1349.
14. Ilson D.H., Motzer R.J., Rodriguez E., Chaganti R.S., Bosl G.J. Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site. Semin Oncol 1993, 20:229-237.
15. Bloom G., Yang I.V., Boulware D., Kwong K.Y., Coppola D., Eschrich S., Quackenbush J., Yeatman T.J. Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol 2004, 164:9-16.
16. Ramaswamy S., Tamayo P., Rifkin R., Mukherjee S., Yeang C.H., Angelo M., Ladd C., Reich M., Latulippe E., Mesirov J.P., et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 2001, 98:15149-15154.
17. Shedden K.A., Taylor J.M., Giordano T.J., Kuick R., Misek D.E., Rennert G., Schwartz D.R., Gruber S.B., Logsdon C., Simeone D., et al. Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework. Am J Pathol 2003, 163:1985-1995.
18. Tothill R.W., Kowalczyk A., Rischin D., Bousioutas A., Haviv I., van Laar R.K., Waring P.M., Zalcberg J., Ward R., Biankin A.V., et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005, 65:4031-4040.
19. Rosenfeld N., Aharonov R., Meiri E., Rosenwald S., Spector Y., Zepeniuk M., Benjamin H., Shabes N., Tabak S., Levy A., et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008, 26:462-469.
20. Ojala K.A., Kilpinen S.K., Kallioniemi O.P. Classification of unknown primary tumors with a data-driven method based on a large microarray reference database. Genome Med 2011, 3:63.
21. Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., Iyer V., Jeffrey S.S., Van de Rijn M., Waltham M., et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000, 24:227-235.
22. Horlings H.M., van Laar R.K., Kerst J.M., Helgason H.H., Wesseling J., van der Hoeven J.J., Warmoes M.O., Floore A., Witteveen A., Lahti-Domenici J., et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 2008, 26:4435-4441.
23. Ma X.J., Patel R., Wang X., Salunga R., Murage J., Desai R., Tuggle J.T., Wang W., Chu S., Stecker K., et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med 2006, 130:465-473.
24. Talantov D., Baden J., Jatkoe T., Hahn K., Yu J., Rajpurohit Y., Jiang Y., Choi C., Ross J.S., Atkins D., et al. A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J Mol Diagn 2006, 8:320-329.
25. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
26. Quon G., Morris Q. ISOLATE: a computational strategy for identifying the primary origin of cancers using high-throughput sequencing. Bioinformatics 2009, 25:2882-2889.
27. Sultan M., Schulz M.H., Richard H., Magen A., Klingenhoff A., Scherf M., Seifert M., Borodina T., Soldatov A., Parkhomchuk D., et al. A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 2008, 321:956-960.
28. Wang Z., Gerstein M., Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009, 10:57-63.
29. Pentheroudakis G., Golfinopoulos V., Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 2007, 43:2026-2036.
30. Briasoulis E., Pavlidis N. Cancer of unknown primary origin. Oncologist 1997, 2:142-152.
31. Abbruzzese J.L., Abbruzzese M.C., Lenzi R., Hess K.R., Raber M.N. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995, 13:2094-2103.
32. Stewart J.F., Tattersall M.H., Woods R.L., Fox R.M. Unknown primary adenocarcinoma: incidence of overinvestigation and natural history. Br Med J 1979, 1:1530-1533.
33. Le Chevalier T., Cvitkovic E., Caille P., Harvey J., Contesso G., Spielmann M., Rouesse J. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med 1988, 148:2035-2039.
34. Hamilton C.S., Langlands A.O. ACUPS (adenocarcinoma of unknown primary site): a clinical and cost benefit analysis. Int J Radiat Oncol Biol Phys 1987, 13:1497-1503.
35. Kirsten F., Chi C.H., Leary J.A., Ng A.B., Hedley D.W., Tattersall M.H. Metastatic adeno or undifferentiated carcinoma from an unknown primary site-natural history and guidelines for identification of treatable subsets. Q J Med 1987, 62:143-161.
36. Nystrom J.S., Weiner J.M., Wolf R.M., Bateman J.R., Viola M.V. Identifying the primary site in metastatic cancer of unknown origin. Inadequacy of roentgenographic procedures. JAMA 1979, 241:381-383.
37. Moertel C.G., Reitemeier R.J., Schutt A.J., Hahn R.G. Treatment of the patient with adenocarcinoma of unknown origin. Cancer 1972, 30:1469-1472.
38. Osteen R.T., Kopf G., Wilson R.E. In pursuit of the unknown primary. Am J Surg 1978, 135:494-497.
39. Kothari V., Wei I., Shankar S., Kalyana-Sundaram S., Wang L., Ma L.W., Vats P., Grasso C.S., Robinson D.R., Wu Y.M., et al. Outlier kinase expression by RNA sequencing as targets for precision therapy. Cancer Discov 2013, 3:280-293.
40. International Cancer Genome Consortium 2014, http://www.icgc.org.
41. The Cancer Genome Atlas 2014, http://cancergenome.nih.gov.
42. R language 2014, http://www.R-project.org.
43. Sing T., Sander O., Beerenwinkel N., Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2005, 21:3940-3941.
44. Everitt B.S., Hothorn T. A handbook of statistical analyses using R 2010, CRC PressINC, [Vol.].
45. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control 1974, 19:716-723.
46. McCullagh P., Nelder J.A. Generalized linear model 1989, Chapman & Hall, [Vol.].
47. Perkins N.J., Schisterman E.F. The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006, 163:670-675.
48. de Hoon M.J., Imoto S., Nolan J., Miyano S. Open source clustering software. Bioinformatics 2004, 20:1453-1454.
49. Eisen M. TreeView 2002, http://rana.lbl.gov/EisenSoftware.htm.
50. Pesquita C., Faria D., Falcao A.O., Lord P., Couto F.M. Semantic similarity in biomedical ontologies. PLoS Comput Biol 2009, 5:e1000443.
51. Eeles R.A., Kote-Jarai Z., Giles G.G., Olama A.A.A., Guy M., Jugurnauth S.K., Mulholland S., Leongamornlert D.A., Edwards S.M., Morrison J., et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008, 40:316-321.
52. Edwards S., Campbell C., Flohr P., Shipley J., Giddings I., Te-Poele R., Dodson A., Foster C., Clark J., Jhavar S., et al. Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. Br J Cancer 2005, 92:376-381.
53. Liu X.F., Olsson P., Wolfgang C.D., Bera T.K., Duray P., Lee B., Pastan I. PRAC: A novel small nuclear protein that is specifically expressed in human prostate and colon. Prostate 2001, 47:125-131.
54. Bhatia-Gaur R., Donjacour A.A., Sciavolino P.J., Kim M., Desai N., Young P., Norton C.R., Gridley T., Cardiff R.D., Cunha G.R., et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev 1999, 13:966-977.
55. Bowen C., Bubendorf L., Voeller H.J., Slack R., Willi N., Sauter G., Gasser T.C., Koivisto P., Lack E.E., Kononen J., et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000, 60:6111-6115.
56. Ellwood-Yen K., Graeber T.G., Wongvipat J., Iruela-Arispe M.L., Zhang J., Matusik R., Thomas G.V., Sawyers C.L. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003, 4:223-238.
57. He W.W., Sciavolino P.J., Wing J., Augustus M., Hudson P., Meissner P.S., Curtis R.T., Shell B.K., Bostwick D.G., Tindall D.J., et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997, 43:69-77.
58. Nelson W.G., De Marzo A.M., Isaacs W.B. Prostate cancer. N Engl J Med 2003, 349:366-381.
59. Wang X., Julio M.K.D., Economides K.D., Walker D., Yu H., Halili M.V., Hu Y.P., Price S.M., Abate-Shen C., Shen M.M. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009, 461:495-500.
60. Gaut J.P., Crimmins D.L., Lockwood C.M., McQuillan J.J., Ladenson J.H. Expression of the Na+/K+- transporting ATPase gamma subunit FXYD2 in renal tumors. Mod Pathol 2013, 26:716-724.
61. Laurent E., McCoy Iii J.W., Macina R.A., Liu W., Cheng G., Robine S., Papkoff J., Lambeth J.D. Nox1 is over-expressed in human colon cancers and correlates with activating mutations in K-Ras. Int J Cancer 2008, 123:100-107.
62. Kamata T. Roles of Nox1 and other Nox isoforms in cancer development. Cancer Sci 2009, 100:1382-1388.
63. Leu J.I., Crissey M.A.S., Taub R. Massive hepatic apoptosis associated with TGF-β1 activation after Fas ligand treatment of IGF binding protein-1-deficient mice. J Clin Invest 2003, 111:129-139.
64. Borlak J., Meier T., Halter R., Spanel R., Spanel-Borowski K. Epidermal growth factor-induced hepatocellular carcinoma: Gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 2005, 24:1809-1819.
65. Chuman Y., Bergman A., Ueno T., Saito S., Sakaguchi K., Alaiya A.A., Franzen B., Bergman T., Arnott D., Auer G., et al. Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas. FEBS Lett 1999, 462:129-134.
66. Hirano T., Auer G., Maeda M., Hagiwara Y., Okada S., Ohira T., Okuzawa K., Fujioka K., Franzen B., Hibi N., et al. Human tissue distribution of TA02, which is homologous with a new type of aspartic proteinase, napsin A. Jpn J Cancer Res 2000, 91:1015-1021.
67. Ueno T., Linder S., Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer 2003, 88:1229-1233.
68. Habener J.F., Kemp D.M., Thomas M.K. Minireview: transcriptional regulation in pancreatic development. Endocrinology 2005, 146:1025-1034.
69. Sander N., Sussel L., Conners J., Scheel D., Kalamaras J., Dela Cruz F., Schwitzgebel V., Hayes-Jordan A., German M. Homeobox gene Nkx6.1 lies downstream of Nkx2.2 in the major pathway of β-cell formation in the pancreas. Development 2000, 127:5533-5540.
70. Schwitzgebel V.M., Scheel D.W., Conners J.R., Kalamaras J., Lee J.E., Anderson D.J., Sussel L., Johnson J.D., German M.S. Expression of neurogenin3 reveals an islet cell precursor population in the pancreas. Development 2000, 127:3533-3542.
71. Yang L., Li S., Hatch H., Ahrens K., Cornelius J.G., Petersen B.E., Peck A.B. In vitro trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells. Proc Natl Acad Sci U S A 2002, 99:8078-8083.
72. Moss S.F., Lee J.W., Sabo E., Rubin A.K., Rommel J., Westley B.R., May F.E.B., Gao J., Meitner P.A., Tavares R., et al. Decreased expression of gastrokine 1 and the trefoil factor interacting protein TFIZ1/GKIM2 in gastric cancer: influence of tumor histology and relationship to prognosis. Clin Cancer Res 2008, 14:4161-4167.
73. Oien K.A., McGregor F., Butler S., Ferrier R.K., Downie I., Bryce S., Burns S., Keith W.N. Gastrokine I is abundantly and specifically expressed in superficial gastric epithelium, down-regulated in gastric carcinoma, and shows high evolutionary conservation. J Pathol 2004, 203:789-797.
74. Xing R., Li W., Cui J., Zhang J., Kang B., Wang Y., Wang Z., Liu S., Lu Y. Gastrokine 1 induces senescence through p16/Rb pathway activation in gastric cancer cells. Gut 2012, 61:43-52.
75. Yoon J.H., Kang Y.H., Choi Y.J., Park I.S., Nam S.W., Lee J.Y., Lee Y.S., Park W.S. Gastrokine 1 functions as a tumor suppressor by inhibition of epithelial-mesenchymal transition in gastric cancers. J Cancer Res Clin Oncol 2011, 137:1697-1704.
76. Yoon J.H., Song J.H., Zhang C., Jin M., Kang Y.H., Nam S.W., Lee J.Y., Park W.S. Inactivation of the Gastrokine 1 gene in gastric adenomas and carcinomas. J Pathol 2011, 223:618-625.
77. Kunzelmann K., Kongsuphol P., Aldehni F., Tian Y., Ousingsawat J., Warth R., Schreiber R. Bestrophin and TMEM16-Ca2+ activated Cl- channels with different functions. Cell Calcium 2009, 46:233-241.
78. Spitzner M., Martins J.R., Soria R.B., Ousingsawat J., Scheidt K., Schreiber R., Kunzelmann K. Eag1 and bestrophin 1 are up-regulated in fast-growing colonic cancer cells. J Biol Chem 2008, 283:7421-7428.
79. Chung W., Kwabi-Addo B., Ittmann M., Jelinek J., Shen L., Yu Y., Issa J.P.J. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One 2008, 3.
80. Furuta J., Nobeyama Y., Umebayashi Y., Otsuka F., Kikuchi K., Ushijima T. Silencing of peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res 2006, 66:6080-6086.
81. Vasiljević N., Wu K., Brentnall A.R., Kim D.C., Thorat M.A., Kudahetti S.C., Mao X., Xue L., Yu Y., Shaw G.L., et al. Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers 2011, 30:151-161.
82. Rodríguez D., Ramsay A.J., Quesada V., Garabaya C., Campo E., Freije J.M.P., López-Otín C. Functional analysis of sucrase-isomaltase mutations from chronic lymphocytic leukemia patients. Hum Mol Genet 2013, 22:2273-2282.
83. Prakash T., Sharma V.K., Adati N., Ozawa R., Kumar N., Nishida Y., Fujikake T., Takeda T., Taylor T.D. Expression of conjoined genes: another mechanism for gene regulation in eukaryotes. PLoS One 2010, 5:e13284.
84. Poulin F., Brueschke A., Sonenberg N. Gene fusion and overlapping reading frames in the mammalian genes for 4E-BP3 and MASK. J Biol Chem 2003, 278:52290-52297.
85. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53:549-554.
86. Bos J.L. ras Oncogenes in human cancer: a review. Cancer Res 1989, 49:4682-4689.
87. Hingorani S.R., Petricoin Iii E.F., Maitra A., Rajapakse V., King C., Jacobetz M.A., Ross S., Conrads T.P., Veenstra T.D., Hitt B.A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4:437-450.
88. Morton J.P., Mongeau M.E., Klimstra D.S., Morris J.P., Yie C.L., Kawaguchi Y., Wright C.V.E., Hebrok M., Lewis B.C. Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci U S A 2007, 104:5103-5108.
89. Kim D.W., Lassar A.B. Smad-dependent recruitment of a histone deacetylase/Sin3A complex modulates the bone morphogenetic protein-dependent transcriptional repressor activity of Nkx3.2. Mol Cell Biol 2003, 23:8704-8717.
90. Lefebvre V., Smits P. Transcriptional control of chondrocyte fate and differentiation. Birth Defects Res C Embryo Today 2005, 75:200-212.
91. Murtaugh L.C., Zeng L., Chyung J.H., Lassar A.B. The chick transcriptional repressor Nkx3.2 acts downstream of Shh to promote BMP-dependent axial chondrogenesis. Dev Cell 2001, 1:411-422.
92. Zeng L., Kempf H., Murtaugh L.C., Sato M.E., Lassar A.B. Shh establishes an Nkx3.2/Sox9 autoregulatory loop that is maintained by BMP signals to induce somitic chondrogenesis. Genes Dev 2002, 16:1990-2005.
93. Katoh Y., Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 2009, 9:873-886.
94. Lee C.J., Dosch J., Simeone D.M. Pancreatic cancer stem cells. J Clin Oncol 2008, 26:2806-2812.
95. Thayer S.P., Di Magliano M.P., Heiser P.W., Nielsen C.M., Roberts D.J., Lauwers G.Y., Qi Y.P., Gysin S., Fernández-del Castillo C., Yajnik V., et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425:851-856.
96. Hahn S.A., Schutte M., Shamsul Hoque A.T.M., Moskaluk C.A., Da Costa L.T., Rozenblum E., Weinstein C.L., Fischer A., Yeo C.J., Hruban R.H., et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271:350-353.
97. Hezel A.F., Kimmelman A.C., Stanger B.Z., Bardeesy N., DePinho R.A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006, 20:1218-1249.
98. Rozenblum E., Schutte M., Goggins M., Hahn S.A., Panzer S., Zahurak M., Goodman S.N., Sohn T.A., Hruban R.H., Yeo C.J., et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997, 57:1731-1734.
99. Wilentz R.E., Iacobuzio-Donahue C.A., Argani P., McCarthy D.M., Parsons J.L., Yeo C.J., Kern S.E., Hruban R.H. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000, 60:2002-2006.
100. Mahadevan D., Von Hoff D.D. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007, 6:1186-1197.